Chemicals & Small Molecules

MOG peptide (35-55) amide, a myelin oligodendrocyte glycoprotein (MOG) fragment spanning amino acids 35 to 55, selectively stimulates CD4+ T cell expansion and induces experimental autoimmune encephalomyelitis (EAE) in animal models [1] [2] [3].

ELOVL6-IN-1 is a potent, selective, and orally active inhibitor of ELOVL6, exhibiting dose-dependent inhibition of mouse ELOVL6 with an IC50 of 0.350 μM and acting as a noncompetitive inhibitor with respect to malonyl-CoA (Ki=994 nM) and palmitoyl-CoA [1].

Bleximenib oxalate (Menin-MLL inhibitor 24 oxalate) is a selective and highly efficient menin-MLL inhibitor. It shows antiproliferative activity in acute lymphoblastic leukemia (ALL) cell lines and inhibits the binding of the menin-KMT2A complex to chromatin at the target gene promoter.

NH2-UAMC1110 TFA is a derivative of UAMC1110 bearing an aminobutoxy group for the synthesis of FAPI-QS. UAMC1110 is a novel selective fibroblast-activated protein (fap) inhibitor exhibiting low nanomolar inhibition of the related dipeptidyl peptidases (dpps), dppiv, dpp9, dppii, and (prep). dppiv, dpp9, dppii, and (prep).

TRAF6 peptide TFA, a specific inhibitor of the TRAF6-p62 interaction, significantly inhibits NGF-dependent ubiquitination of TrkA. This peptide demonstrates promising research applications in various neurological disorders, including Alzheimer's disease (AD), Parkinson's, ALS, head trauma, epilepsy, and stroke [1].

Anti-Mouse TNF alpha Antibody (TN3-19.12) is a mouse-derived IgG antibody against TNF alpha.

Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.

Inclacumab (Anti-Human selectin P Recombinant Antibody) is a fully humanized IgG4 monoclonal antibody that selectively binds to P-selectin. Inclacumab inhibits platelet leukocyte aggregation induced by thrombin receptor-activating peptide (TRAP) or adenosine diphosphate (ADP). Inclacumab inhibits platelet leukocyte aggregation induced by thrombin receptor activating peptide (TRAP) or adenosine diphosphate (ADP).

IMAB027 (ASP1650) is a selective monoclonal antibody against CLDN6 (Claudin 6) with antitumor activity that induces death of CLDN6+ cancer cells through antibody-dependent and complement-dependent cytotoxicity.